Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21220699 | 1.00 | OPRM1 (0.46) | OPRM1OPRK1OPRD1SIGMAR1SCN1A | |
| SCHEMBL21220701 | 1.00 | OPRM1 (0.46) | OPRM1OPRK1OPRD1SIGMAR1SCN1A | |
| SCHEMBL21220368 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL23700168 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL21220335 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL23700157 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL23700169 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL21220371 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL21224915 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 | |
| SCHEMBL21220374 | 0.82 | FUCA1 (0.43) | OPRM1SIGMAR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033394-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | ALKERMES, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11180455-B2 | Compounds for the treatment of pain | ALKERMES, INC. | 2021-11-23 | — | — | US | disclosed |
| US-20200255383-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-13 | — | — | US | disclosed |
| US-10604489-B2 | Compounds for the treatment of pain | ALKERMES, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190241524-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604489-B2 | Compounds for the treatment of pain | OPRK1, OPRL1, ACHE | OPRM1 7/4885OPRK1 1/4885OPRD1 4/4885 |
| US-20190241524-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | OPRK1, OPRL1, ACHE | OPRM1 7/4885OPRK1 1/4885OPRD1 4/4885 |
| US-11180455-B2 | Compounds for the treatment of pain | OPRK1, OPRL1, ACHE | OPRM1 7/4885OPRK1 1/4885OPRD1 4/4885 |
| US-20220033394-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | OPRK1, OPRL1, ACHE | OPRM1 7/4885OPRK1 1/4885OPRD1 4/4885 |
| US-20200255383-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | OPRK1, OPRL1, ACHE | OPRM1 7/4885OPRK1 1/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.